+18.7%
HPQ vs MRNA
+511.3%
-492.6%
-36.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.2% | -2.2% | +4.5% | +2.2% |
| 7D | +6.9% | +5.5% | +1.5% | +6.9% |
| 30D | +14.4% | +158.7% | -144.3% | +14.0% |
| 3M | +25.6% | +182.1% | -156.5% | +24.0% |
| 6M | +75.0% | +151.8% | -76.8% | +73.5% |
| YTD | +50.7% | +393.6% | -342.9% | +42.8% |
| 1Y | +18.7% | +499.5% | -480.8% | +9.8% |
| All | +18.7% | +511.3% | -492.6% | +9.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling